In recent years there has been a paradigm shift in our understanding of the epidemiology and clinical features of hepatitis E virus (HEV) infection. Once classically described as an acute hepatitis associated with waterborne outbreaks in areas of poor sanitation, HEV is now recognised to be endemic in Europe and is probably zoonotic in origin. Evidence for transfusion-transmitted HEV has prompted the introduction of blood donor screening in a number of countries, but the risk to the haematology patient from food sources remains. The aim of this review therefore, is to equip the clinical haematologist with the knowledge required to diagnose HEV infection and to aid decision-making in patient management. The article also provides information on addressing patient concerns about their risk of acquiring hepatitis E and how this risk can be mitigated.
Why is hepatitis E so topical?
In 1978 an outbreak of acute hepatitis affected 52 000 people in Kashmir, India. The compressed epidemic curve of the outbreak, suggesting a point source origin with limited person to person spread, was different to that observed with hepatitis A (Khuroo, 2011) . Subsequently, scientists investigating an outbreak with similar features in Afghanistan, ingested patient faecal samples in an attempt to identify the agent responsible. Transmission and resulting infection with the viral pathogen, later named hepatitis E, was confirmed by immune electron microscopy (Balayan et al, 1983) .
Hepatitis E virus (HEV) is a small (27-34 mm) singlestranded RNA virus approximately 7Á2 kb in length. The genome of the virus was first sequenced in 1990 and is known to consist of a 5 0 cap, a 35 nucleotide 5 0 noncoding
region, three open reading frames (ORFs) and a 3 0 non coding region of~79 nucleotides (nt) followed by a poly(A) tail. The ORF 1 region (~5000 nt) encodes a non-structural polyprotein, ORF2 (~1920 nt) encodes the virus capsid protein, while ORF3 (~340 nt) overlaps the 5 0 end of ORF2 and encodes a phosphoprotein that interacts with cellular signalling proteins (Reyes et al, 1990 ) Successful cell culture of HEV has only recently been reported (Johne et al, 2016) . In Europe, for many years HEV was classically described as a travel-associated infection linked with consuming faecally-contaminated water or shellfish. The first challenge to this dogma came in 1997 with the discovery of a HEV in pigs (Meng et al, 1997) . Further studies confirming that animals not only act as reservoirs for HEV but can also be a transmission source, have significantly altered our understanding of the epidemiology and clinical presentation of this virus (Renou et al, 2014) . It is now widely acknowledged that HEV is endemic in both humans and swine in Europe and in 2008 the first report of chronic HEV infection in organ transplant recipients was published (Kamar, 2008) . Reports of transfusion-transmitted HEV infections and increasing media focus on HEV as a food safety issue have led to a growing awareness amongst medical professionals and the general public of this viral pathogen.
Epidemiology
There are five genotypes of HEV (I, II, III, IV, VII) currently recognised as causing human infection.
Hepatitis E Genotypes (G) I and II are human only pathogens and, although person to person transmission can occur, the dominant mode of infection is via consumption of food or water contaminated by human faecal matter. These genotypes are highly endemic in Asia (GI), Africa and Central America (GII), and are estimated to cause~20 million infections each year (Rein et al, 2012) .
In contrast, hepatitis E Genotypes III and IV can infect both humans and animals. HEV GIII is the dominant genotype in Europe and the US, and there has been a shift from HEV GI to GIV evident in Japan and China in recent years. . Domestic pigs are thought to be the primary reservoir of HEV GIII infection, with seroprevalence within some European pig herds of over 90%. However, the virus has also been found in wild boar, rabbits and deer (van der Poel, 2014; Grierson et al, 2015) . Although Anti-IgG antibodies have been detected in household pets, such as dogs, cats and rabbits, no confirmed cases of HEV transmission have been reported and the risk from companion animals is unknown (Peralta et al, 2009; McElroy et al, 2015; Abravanel et al, 2017) .
To date, only one human case of hepatitis E Genotype VII infection has been published. The infection, in an immunosuppressed individual, was suspected to have been acquired through consumption of camel meat or milk. As HEV GVII has been documented to circulate widely in camels, it is likely that human zoonotic infection with GVII may be underreported (Lee et al, 2016) .
Seroprevalence rates for HEV across European countries varies considerably depending on the cohort studied, the serology assay used and even between geographic regions within countries. A number of blood donor studies have been performed and provide useful data (Table I) 
Routes of transmission
In Europe, the two most significant transmission pathways are through the food chain and unscreened blood and tissue donation. Person-to-person transmission of hepatitis E in household contacts is infrequent and more likely associated with a shared source exposure (Aggarwal & Naik, 1994; Somani et al, 2003) .
HEV and substances of human origin
The first UK case of HEV transmission from a blood component was reported in 2006 and across Europe cases of HEV transmission have been associated with red cells, platelets and Intercept-treated fresh frozen plasma (Boxall et al, 2006; Hauser et al, 2014; Huzly et al, 2014) . In South East England, retrospective screening of 225 000 blood donations identified 79 viraemic donors (1:2848). The donations were used to prepare 129 blood components, of which 62 were transfused. Follow-up of 43 recipients showed 18 (42%) had evidence of infection, with 10 patients having persistent viraemia (detectable levels of HEV RNA) at least 10 weeks after transfusion (Hewitt et al, 2014) . Ireland was the first country to introduce donor screening for HEV in 2013, with almost 25 000 individual donations tested in an 18 months period and five confirmed HEV RNA cases detected (1:4997) (O'Riordan et al, 2016) . Currently Ireland, the UK and the Netherlands have universal blood donor screening, with a number of other countries opting for selective screening policies (Domanovic et al, 2017) . Blood services adopt HEV RNA screening of donor samples on either an individual donation (ID) or pooled testing basis. In the UK, donors with confirmed HEV are deferred for 6 months from the date of first detection of HEV RNA. However, if a previously confirmed HEV-infected donor is tested prior to the end of the 6-month deferral period and found to be HEV RNA negative and HEV IgG positive, the donor may be reinstated immediately (Joint UK Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee [JPAC], 2016) .
Eight out of 328 (2Á8%) allogeneic haematopoietic stem cell transplant recipients had evidence of HEV infection related to blood transfusion in a Dutch review. In five of these cases HEV infection was chronic in nature (Versluis et al, 2013) . HEV transmission has also been reported with both hepatic and renal solid organ transplants (Schlosser et al, 2012; Pourbaix et al, 2017) .
HEV in the food-chain
Given the high seroprevalence of HEV IgG in European swine herds, it is not surprising that HEV RNA has been detected in pork products. In the UK, 10% (6/63) of sausages were found to be contaminated (Berto et al, 2012) . In Germany, 4% (8/200) of pig livers and 22% (24/110) of pork/ liver sausages had evidence of HEV RNA (Wenzel et al, 2011; Szabo et al, 2015) . A further study in Italy found 63% (5/8 packets) of pork liver sausage had detectable HEV (di Bartolo et al, 2015) . HEV RNA has also been detected in pork products in Canada, the US and Japan (Yazaki et al, 2003; Feagins et al, 2007; Wilhelm et al, 2014) . In 2014, molecular sequencing confirmed the first foodborne transmission of HEV when the virus was isolated from both a patient and the frozen remnants of a figatelli (raw pork) sausage they had consumed (Renou et al, 2014) . Other animals have also been identified with HEV infection, including rabbits, wild boar and sika deer, and some of these have also been linked to foodborne transmission events (Tei et al, 2003; Li et al, 2005; Abravanel et al, 2017) . In addition to pork consumption, contaminated water may act as a source for HEV infection, particularly where it is used for irrigation of soft fruit and vegetables. The European Union-funded VITAL (Integrated monitoring and control of foodborne viruses in European food supply chains) study demonstrated the presence of HEV RNA in irrigation water, and in fresh lettuce at the point of sale (Maunula et al, 2013) . Polluted water may also lead to viral contamination of shellfish. In Scotland, HEV RNA was detected in 85% (41/48) mussels collected at tidal locations across five sites, including one close to an outfall drain pipe in line with a slaughterhouse (Crossan et al, 2012) . Definitive evidence of a HEV transmission event from shellfish has yet to be reported, however in 2008, an epidemiological investigation of a HEV outbreak on a cruise ship found an association with shellfish consumption on board (Said et al, 2009 ).
Risk of acquiring hepatitis E infection from the food chain
Even in countries where HEV screening is not routinely performed on blood donations, the predominant risk of HEV acquisition is probably through dietary exposure. In the Netherlands, only one in 700 HEV transmissions is probably due to blood transfusion (de Vos et al, 2017) . In South East England, a study predicted the yearly risk of acquiring HEV from a dietary source was one in 500-1000 and it has been calculated that for a patient, more than 13 individual (unscreened) donor components would be required for their transfusion risk to exceed their annual dietary risk (Hewitt et al, 2014; Tedder et al, 2017) .
How will hepatitis E present in my patients?
The minimum oral infectious dose of HEV is unknown. The general incubation period is 15-50 days (mean 40 days) after exposure, although this depends on the route of transmission and the host immune state. In one patient with leukaemia, transaminitis was first observed 7 months after undergoing a transfusion with HEV-contaminated blood products, by which stage retrospective testing showed she had been viraemic for 3 months (Fuse et al, 2015) .
Liver enzyme abnormalities
Given that the vast majority of HEV infections (>90%) are asymptomatic, liver enzyme abnormalities detected during routine monitoring may provide the only prompt to consider the diagnosis. Attempts have been made to determine a threshold for HEV testing in the immunocompetent patient, based on alanine aminotransferase (ALT) levels ranging from 100-300 iu/l, but no clear consensus has been agreed (Harvala et al, 2014; Wallace et al, 2017) . It is generally accepted however, that in the immunocompromised host, only very modest increases in ALT may be evident (Satake et al, 2017) . In patients for whom drug-induced liver injury (DILI) is being considered as a diagnosis, HEV infection should first be excluded. In one large study of 317 patients with DILI, 3% (9) actually had acute HEV infection, a smaller study of 47 patients found HEV in 13% (Dalton et al, 2007; Davern et al, 2011) .
Acute hepatitis
The clinical presentation of acute symptomatic hepatitis E infection is similar to that seen in other forms of viral hepatitis, with features including fever, non-specific malaise and gastrointestinal symptoms, such as vomiting, abdominal pain, anorexia, followed by the onset of jaundice in~75% of patients (Kamar et al, 2014a) . In most immunocompetent adults, the disease is self-limiting with symptomatic and biochemical recovery within 4-6 weeks. Those with underlying chronic liver disease have a high risk of decompensation and excess mortality due to hepatitis E (Dalton, 2012) . In countries where outbreaks of HEV G1 are common, pregnant women are recognised to be at high risk of complications, such as spontaneous abortion, stillbirth and fulminant hepatic failure, with resulting mortality rates of up to 30%. The pathophysiology for this is unclear and mortality due to HEV G3 infection in pregnancy has not been reported to date in Europe (Perez-Gracia et al, 2017).
Persistent HEV infection
The ability of HEV to cause chronic infection, defined as persistent detectable HEV RNA for >3 months, was first reported in solid organ transplant (SOT) recipients in France (Kamar, 2008) . Since then, large multicentre studies have identified that~60% of SOT recipients who become HEV infected will go on to develop chronic disease (Kamar et al, 2014a) . The risk of chronic infection developing in the immunosuppressed haematology patient is less clearly defined. In one case series of 14 patients with haematological Review ª 2018 John Wiley & Sons Ltd malignancy, 9 had spontaneous clearance of their acute HEV infection with 5 having prolonged HEV replication lasting >3 months (Tavitian et al, 2015) .
Chronic HEV infection has also been described in patients with human immunodeficiency virus (HIV), those receiving immunomodulatory therapies and in those treated with chemotherapy for solid tumours (Ollier et al, 2009; Gauss et al, 2012) . No clear associations have been found between any particular immunosuppressive regimen and HEV infection or chronicity, with cases of HEV reported in patients taking ciclosporin, corticosteroids, rituximab and methotrexate (Krain et al, 2014) . Factors, such as low leucocyte, total lymphocyte and T cell counts, are associated with failure to clear HEV in SOT recipients, as are low CD4 counts in the HIV population (Dalton et al, 2009; Kamar et al, 2011) .
In the SOT recipient, chronic HEV infection has been associated with a risk of progressive cirrhosis leading to liver failure requiring transplant (Kamar, 2008) . The development of fibrosis and cirrhosis as a result of chronic HEV infection has also been described in patients with haematological malignancies and post-bone marrow transplantation (Halac et al, 2012; Satake et al, 2017) .
Haematopoietic stem cell transplant (HSCT) recipients
Hepatitis E infection can be mis-or un-diagnosed in this cohort because of the overlapping clinical presentation with hepatic graft-versus-host disease (GvHD) or DILI (Bettinger et al, 2015) . In one Dutch study of 328 allogenic HSCT recipients, 8 cases (2Á4%) of HEV infection were identified. Of these, two patients died of unrelated causes within 2 months of transplant and 5 developed chronic viraemia (defined in that study as persistent detection of HEV RNA for longer than 6 months). It should be noted that, at the time, HEV screening in blood and tissue donations was not routinely performed (Versluis et al, 2013) .
Haematological manifestations as features of hepatitis E virus infection
In recent years there have been increasing reports of extrahepatic manifestations of HEV infection (Table II) . The pathophysiology of these manifestations and definitive proof of causality, e.g. by large case-controlled studies, has yet to be confirmed. Many of the observations derive from case series, serological studies, limited in vitro data and animal models. (Pischke et al, 2017) . To date a number of haematological manifestations as features of HEV infection have been described.
Thrombocytopenia
This association of hepatitis E infection with severe thrombocytopenia is well described in case reports with both HEV Genotype I and Genotype III infection. It is thought to occur most likely through an immune-mediated process (Bazerbachi et al, 2016) . In the South of France, a hyperendemic area for HEV GIII, three patients with severe thrombocytopenia presented within a 6-month period. In addition to their isolated thrombocytopenia (1, 10Á13 9 10 9 / l at presentation), all had transaminase elevations, but only one was jaundiced. HEV infection was confirmed by serology and detection of HEV RNA in serum. While no specific treatment was required for two patients, whose platelet count rapidly increased to normal levels by day 12, one patient recovered following 8 days of steroid treatment (Fourquet et al, 2010) . In a review of 106 patients with non-travel associated hepatitis E in Cornwall, other abnormal haematology findings included lymphocytosis (13Á2%), lymphopenia (7Á5%) and mild thrombocytopenia (11Á3%) at the time of their presentation. In three of these cases the platelet count was <100 9 10 9 /l, with the lowest count recorded as 40 9 10 9 /l (Woolson et al, 2014) .
Anaemia
Hepatitis E virus has been associated with autoimmune haemolytic anaemia (AIHA) in a limited number of case reports. In two cases reported from Asia, the diagnosis was made on the basis of serology results after other causes of anaemia and haemolysis were excluded; both made a full recovery with supportive treatment (Mishra et al, 2007; Thapa & Ghosh, 2009) . A more recent publication from the USA described a young man with AIHA whose significant history of raw oyster consumption prompted testing to confirm acute HEV infection (Leaf et al, 2017) . Non-immune haemolytic anaemia due to glucose 6-phosphate dehydrogenase (G6PD) deficiency can occur during HEV infection. Cases reported to date have all been in HEV GI endemic areas where G6PD deficiency is also common (Monga et al, 2003; Au & Chan, 2012) . In one child, the diagnosis of G6PD deficiency was made only after the presentation of acute HEV with severe intravascular haemolysis complicated by acute renal failure (Tomar et al, 2015) .
Hepatitis E-associated aplastic anaemia has been described in three cases. In one such case, confirmed as HEV GIII by molecular sequencing, the patient made a full recovery following treatment with ciclosporin, anti-thymocyte globulin, corticosteroids, filgastrim and transfusion support (Amarapurkar & Amarapurkar, 2002; Shah et al, 2012; Zylberman et al, 2015) . A report of pure red cell aplasia in a 63-year-old Chinese man with acute liver failure due to HEV has also been published (Li & Wang, 2011) ; the patient improved with supportive care.
Monoclonal gammopathy of uncertain significance
A possible association between HEV and Monoclonal Gammopathy of Uncertain Significance (MGUS) was raised by a UK study of 65 patients with acute HEV who had serum protein electrophoresis (SPEP) performed at time of diagnosis (Woolson et al, 2014) . A monoclonal paraprotein was found in 17 (26Á2%); however, of note, none of these patients had been tested for MGUS prior to their presentation with acute HEV. None of the patients had clinical or laboratory findings suggestive of lymphoma or myeloma and bone marrow biopsies were not performed. Follow up SPEP was available in six patients, of whom only 2 had evidence of persistent paraprotein (at 42 and 54 months, respectively). One of these patients subsequently developed acute myeloid leukaemia. The authors of this study postulate that an immune deficit associated with MGUS may predispose to the development of symptomatic hepatitis E infection or that HEV may have a causal role in MGUS, however further research is required.
Additional haematological manifestations
In France, two cases of haemophagocytic syndrome (HPS) have been reported in patients with HEV infection, both of whom had underlying comorbidities (splenic lymphoma and rheumatoid arthritis on tocilizumab infusion) (Leroy et al, 2015; Bazerbachi et al, 2016) . Dual infection with hepatitis A virus and HEV has also been associated with HPS (Kaur et al, 2011) .
One case of fatal HEV-associated agranulocytosis has been reported in a 70-year-old, previously immunocompetent, Spanish patient infected with HEV Genotype III (Lens et al, 2015) .
An interesting association between chronic hepatitis E infection and primary cutaneous CD30(+) T cell lymphoproliferative disorder (T-LPD) in a patient has recently been described. In this case, treatment of chronic HEV infection resulted in remission of their T-LPD and the patient remained in complete remission after achieving a sustained viral response to Ribavirin and interferon therapy (Mallet et al, 2017) .
Neurological and other extrahepatic manifestations of hepatitis E virus
Hepatitis E is more than just a hepatotropic virus, and has been demonstrated to infect neurons and brain tissue (Zhou et al, 2017) . The clinical association between hepatitis E and neurological conditions, including Guillain-Barr e Syndrome, neuralgic amyotrophy and encephalitis/myelitis, has been widely reported .
Hepatitis E virus has also been found in patients with mixed cryoglobulinaemia and a recent systematic review of 15 cases concluded that a causal relationship is highly probable, with the role of HEV in such cases probably underrecognised (Bazerbachi et al, 2017) . Renal manifestations, such as membranoproliferative glomerulonephritis (with or without cryoglobulinaemia) and membranous glomerulonephritis, have also been associated with HEV infection . Other recognised extrahepatic manifestations include acute pancreatitis, however further studies are required to confirm the role of HEV reportedly associated with musculoskeletal disorders and immune-mediated thyroiditis (Bazerbachi et al, 2016) .
How to test for hepatitis E virus infection?
Laboratory confirmation of HEV infection is based on direct detection of HEV RNA in serum/faeces and/or by serological methods. In the immune-competent individual, anti-HEV IgM becomes detectable prior to the onset of symptomatic illness and remains detectable for 3-6 months. Anti-HEV IgG becomes detectable soon after the IgM and can persist for life. Although difficult to determine accurately, it appears that the duration of HEV viraemia in a healthy adult is short-lived, with a mean duration of viraemia in asymptomatic donor studies of 6Á5-9Á5 weeks Tedder et al, 2016) . HEV RNA can be detected in stool for approximately 1 week before and up to 6 weeks after the onset of symptomatic illness (Arends et al, 2014) . The World Health Organization has recently developed an international standard facilitating the quantification of HEV RNA viral loads. This is particularly useful in monitoring viral clearance in patients with, or at risk of, chronic HEV infection (Baylis et al, 2013) .
There are a number of caveats in interpreting HEV serology in the haematology patient cohort. Immunosuppressed patients may not mount an antibody response despite detectable HEV viraemia and therefore HEV RNA polymerase chain reaction should always be performed when HEV is suspected (Kamar et al, 2013) . Conversely, false positive IgM results have been reported in cases of Epstein-Barr virus and cytomegalovirus infection, probably due to polyclonal B cell stimulation (Hyams et al, 2014) .
How to manage hepatitis E infection?
In immunocompetent patients, hepatitis E is a self-limiting disease and, in general, no specific treatment is required.
In the immunocompromised, evidence for management strategies has largely been drawn from studies of SOT recipients, where the natural course of HEV infection has been well described. Given that 30% of this cohort will clear their HEV infection spontaneously within 3 months, an initial period of observation and monitoring is recommended in most cases, before considering reduction of immunosuppression and/or use of an antiviral agent, (McPherson et al, 2018) . Reduction in immunosuppressive therapy, mainly immunosuppressants that target T cells, has resulted in HEV clearance in almost 30% of SOT recipients with chronic hepatitis E. Where antiviral therapy is indicated, Ribavirin has become the antiviral treatment of choice due to its relatively good safety profile, low cost and high efficacy in the SOT recipient cohort (Kamar et al, 2014b) . The exact mechanism by which Ribavirin has an effect on HEV in vivo is unknown and its use in the management of HEV infection is offlicence as no clinical trials have been performed. Pegylated interferon alpha has also been used in a small number of cases to treat chronic HEV infection and may have a role where Ribavirin therapy has been unsuccessful (Peters Van Ton et al, 2015; Donnelly et al, 2017) .
In the absence of established guidelines, management strategies for hepatitis E in the haematology patient will be on a case-by-case basis. In acute infection, monitoring of HEV RNA viral load and antibody titres (declining RNA levels and HEV IgG seroconversion) may be helpful in clinical decision-making and in the early identification of those patients at risk of developing chronic infection. Ribavirin may be used in chronic infection and where immune treatments cannot be postponed, the early use of this antiviral has been shown to facilitate the therapeutic schedule. In one centre, among 12 Ribavirin treated patients, 9 were able to complete their planned treatment, which included stem cell transplant (Tavitian et al, 2015) .
For chronic infection, the optimum dose and duration of treatment with Ribavirin is unknown, however in SOT recipients, a minimum of 3 months is recommended with monitoring of HEV RNA at day 7 and monthly thereafter. Therapy is discontinued at 3 months as long as HEV RNA has not been detected in plasma and stool when tested at 2 and 3 months of treatment. To confirm a sustained virological response it is suggested to test plasma and stool for HEV RNA at three and six months after stopping antiviral treatment (McPherson et al  2018) . Testing for the presence of HEV RNA in stool is of particular importance in confirming clearance of HEV as prolonged faecal shedding in the absence of viraemia has been reported in patients, including those with haematological malignancies (Ambrosioni et al, 2014) .
Haemolysis is a significant side effect associated with Ribavirin administration. It is an extravascular event, caused by oxidative damage to intracellular red blood cell metabolic pathways, and occurs in up to 10% of recipients but may be exacerbated further in the context of recent HSCT (Russmann et al, 2006; Ankcorn & Tedder, 2017) Treatment failure with Ribavirin has been associated with the selection of resistant HEV variants carrying a genetic mutation (G1364R) that allows increased replication in the liver; however, the wider implication of this are as yet unknown (Debing et al, 2014; Todt et al, 2016) .
Infection prevention and control
Nosocomial transmission of HEV in a haematology ward has been reported. Molecular sequencing supported the association between a chronically infected patient and another with acute leukaemia who developed HEV hepatitis. A retrospective audit revealed no major breaches of universal hygiene precautions (Mansuy et al, 2009) . In acute self-limiting HEV infection, viral RNA can be shed in stool for up to a month after the onset of jaundice, however persistent shedding can occur in the immunosuppressed haematology patient (Tavitian et al, 2010) . Patients with hepatitis E infection who are admitted to hospital require isolation with dedicated toilet facilities and contact precautions enforced. As long as standard infection prevention and control policies are observed, with particular attention to handwashing, healthcare workers are not at risk of HEV infection.
Risk mitigation and prevention
Identifying risk mitigation actions for HEV in the food-chain is a key priority of the European Food Safety Authority, however the lack of a robust and easily reproducible cell culture system for HEV has made inactivation experiments challenging. Current recommendations suggest thorough cooking of pork, wild boar and deer meat to a safe minimum internal temperature of 71°C for 20 min. Additional recommendations to minimise the risk include: (i) washing hands after handling food products that may have a higher risk of having HEV virus (uncooked liver, liver products and meat); (ii) washing utensils with hot soapy water after preparing a food item with raw meat or liver; (iii) using one cutting board for fresh produce and a separate one for raw meat or liver; (iv) never placing cooked food on a plate that previously held raw meat. This advice should be incorporated into education sessions for patients who are, or are likely to become, immunocompromised. It has also been suggested that dietary advice should be imparted not only to prospective transplant recipients but to their living donors in order to mitigate dietary exposure to HEV and the incipient risk of post-transplant HEV infection (O'Donghaile et al, 2017) . However, this may not always be feasible in the context of donors sourced through international registries. The persistence of HEV in liver and processed meat products, not subjected to cooking but to process technologies (cured, smoked, dried, fermented) is unknown (Ricci et al, 2017) .
The introduction of universal donor screening for HEV in the UK and Ireland will reduce the risk of transmission of HEV via transfused components. In addition, the expert advisory committee on the Safety of Blood, Tissues and Organs (SaBTO) has recommended that that all donors of solid organs and allogeneic haematopoietic stem and progenitor cells (HSPC) be individually screened for hepatitis E viraemia using HEV-Nucleic Acid Testing Advisory Committee on the Safety of Blood, Tissues and Organs, 2016) .
A recombinant vaccine derived from HEV GI is used for those >16 years of age at high risk of HEV infection in China (approved by Chinese Food and Drug Administration in 2011, available since 2012) but to date has not been licensed or approved for use in other countries. The vaccine (Hecolin â , Xiamen Innovax Biotech, Xiamen, China) is comprised of a 239 amino-acid peptide corresponding to part of the capsid protein of HEV GI. A phase III study with almost 113 000 participants found the vaccine to have >95% efficacy for HEV GIV (the dominant genotype in this region) after three doses (Zhu et al, 2010) .
Is reinfection possible?
The possibility of hepatitis E reinfection has been demonstrated in SOT recipients, and those re-infected were found to be a higher risk of developing chronic infection . Reinfection is also possible in the immune competent: a study of plasma donors found two patients who had detectable HEV RNA GIII despite having evidence supporting a prior history of HEV infection (high avidity HEV IgG antibodies and absent HEV IgM response) (Baylis et al, 2015) . The clinical significance of HEV reinfection in the immunocompetent individual is unknown but proabably of negligible consequence.
Is reactivation possible?
To date there has been only one published case of apparent HEV reactivation supported by molecular sequencing. The patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia was documented to have acute HEV prior to allogeneic stem cell transplantation. HEV RNA was not detected for 4 weeks prior to transplant, however, 14 weeks after transplant, reappearance of HEV viraemia was observed, with increasing viral load and modestly elevated serum transaminases. Sequence analysis of HEV viral RNA samples from the initial presentation and post-transplant was >99% homologous, suggesting this was not a reinfection. However, it is possible that HEV infection persisted in this period of apparent remission but at levels which were below What are the optimal management strategies for HEV infection in the haematology cohort?
• Indications for antiviral therapy.
• Optimum dose and duration of antiviral treatment.
• Management of treatment failure, e.g. due to antiviral drug resistance Alternative therapies for HEV
Risk mitigation and prevention of HEV infection
How to prevent HEV in an at-risk population?
• Development of a licensed vaccine and guidelines for use.
• HEV control measures in the food chain. A case series of 36 patients who were HEV IgG positive, HEV RNA negative pre-HSCT did not find any evidence for reactivation when tested at 1, 3 and 6 months post-transplant (Abravanel et al, 2012) . Similarly, a large study of 99 SOT recipients who were HEV IgG positive prior to transplant found no evidence for HEV reactivation (LegrandAbravanel et al, 2011) . Routine screening or prophylaxis for HEV is not recommended in patients awaiting SOT (McPherson et al, 2018) .
Conclusion
Hepatitis E virus is endemic in Europe and, despite the introduction of donor screening policies, the haematology patient will probably remain at significant risk from foodborne sources. Clinicians should be aware of the potential for HEV to present as either acute or chronic infection, with mild or absent clinical symptoms. In an at-risk immunosuppressed patient, the diagnosis should be considered even where liver function tests are only modestly elevated. In addition, abnormal blood indices may be the only presentation in the previously well adult and HEV testing should be performed as part of the work-up of these cases. As awareness of HEV in the haematology cohort increases, further research is required to address gaps in our knowledge (Table III) . As yet, there are no clear guidelines on the use of antiviral therapy in the management of HEV in the haematology cohort, and assessment should be made on a case-by-case basis. Ribavirin has been shown to have some efficacy in achieving clearance of HEV in immunosuppressed patients, but the side effect of haemolytic anaemia can be significant and treatment failure may occur. Evidence to support the development of management strategies for HEV in the haematology patient is required. In addition, further work to mitigate risk in the food chain and the potential implementation of a licensed vaccine is eagerly awaited.
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